恶性肿瘤化疗后所致重度血小板减少给予重组人白细胞介素11临床评价.docVIP

恶性肿瘤化疗后所致重度血小板减少给予重组人白细胞介素11临床评价 　　【摘要】 目的：评价恶性肿瘤患者在化疗后出现重度血小板减少给予重组人白细胞介素11（rhIL-11）的治疗及预防效果。方法：选择58例恶性肿瘤患者，在化疗后出现重度血小板减少后给予rhIL-11治疗（作为治疗周期）；在下一周期化疗结束后48 h所有患者再给予rhIL-11预防性治疗（作为预防治疗周期）。采用自身的对照研究方法评价2个周期患者血小板减少的程度及持续时间。结果：在治疗周期本组的治疗有效率为100%（58/58），而治疗周期及预防治疗周期用药持续时间为（10.9±5.7）d与（5.3±3.8）d，血小板最低值为（25.9±15.7）×109/L与（42.3±18.8）×109/L，血小板减少持续时间为（11.6±5.8）d与（5.2±3.9）d，这些方面比较差异均有统计学意义。在治疗周期本组的不良反应发生率为29.3%（17/58），而在预防治疗周期为25.9%（15/58），两者比较差异无统计学意义。结论：恶性肿瘤患者化疗后应用rhIL-11能够减少化疗后重度血小板减少的发生，也可帮助血小板减少患者的恢复，同时还能缩短血小板减少持续的时间，不良反应轻微，患者耐受性好。 　　【关键词】 恶性肿瘤； 药物化疗； 重度血小板减少； 重组人白细胞介素11 　　Clinical Evaluation of Using Recombinant Human Interleukin 11 for Malignant Tumor Patients after Chemotherapy Induced Severe Thrombocytopenia/WU Meng-yu，JIANG Tao.//Medical Innovation of China，2015，12（04）：132-134 　　【Abstract】 Objective：To evaluate the preventive and curative effects of recombinant human interleukin 11 （rhIL-11） for malignant tumor patients after chemotherapy induced severe thrombocytopenia.Method：58 patients with malignant tumor after chemotherapy induced severe thrombocytopenia were enrolled in the study， in the presence of severe thrombocytopenia after treated were given rhIL-11 （as treatment period）； all the patients in the next cycle of chemotherapy at 48 h after administration were given rhIL-11 preventive treatment （as prevention and treatment period）.The 2 cycle degree of thrombocytopenia and duration were observed by using own control methods.Result：The effective rate of treatment period was 100%（58/58）；the treatment period and the prevention in treatment period on medication duration was respectively（10.9±5.7）d and （5.3±3.8）d；thrombocytopenia duration was respectively（11.6±5.8）d 　　and（5.2±3.9）d； platelet minimum were respectively（25.9±15.7）×109/L and（42.3±18.8）×109/L， the differences were statistically significant（P0.05）.The incidence rate of adverse reaction in treatment period was 29.3%（17/58），and in prevention treatment period was 25.9% （15/58），the difference was not